Overview of the hybrid 82nd Scientific Sessions of the American Diabetes Association
Dr Caroline Day reports on the New Orleans-based hybrid meeting, held on the 3rd-7th June, 2022
DOI:
https://doi.org/10.15277/bjd.2022.391References
ADA programme 2022. https://www.nxtbook.com/tristareventmedia/ADA/advance-program-ada-82nd-scientific-sessions/index.php
ADA Scientific Sessions website https://professional.diabetes.org/scientific-sessions
ADA News https://www.adameetingnews.org/
ADA 82nd Scientific Sessions Abstracts. Diabetes 2022;71: suppl 1. ISSN 0012-179, EISSN 1939-327X. (https://diabetesjournals.org/diabetes/issue/71/Supplement_1).
Jastreboff AM, Aronne LJ, Ahmad NN, et al for the SURMOUNT -1 investigators. Tirzepatide once weekly in the treatment of obesity. New Engl J Med 2022;387:205-16. https://doi.org/10.1056/NEJMoa2206038).
Del Prato S, Kahn SE, Pavo I, et al on behalf of the SURPASS-4 investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. https://doi.org/10.1016/S0140-6736(21)02188-7).
De Block C, Bailey C, Wysham C, et al. TIrzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab 2022 Aug 5. Online ahead of print. https://doi.org/10.1111/dom.14831
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
